Why Apollomics, Inc.’s (APLM) Stock Is Down 7.13%
As of Friday, July 17, Apollomics, Inc.’s APLM share price has dipped by 7.13%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
Commentary & Analysis
Why Apollomics, Inc.’s (APLM) Stock Is Down 21.79%
As of Friday, July 17, Apollomics, Inc.’s APLM share price has dipped by 21.79%, which has investors questioning if this is right time to buy.Tudor Pop
Why Apollomics, Inc.’s (APLM) Stock Is Down 11.96%
As of Tuesday, June 23, Apollomics, Inc.’s APLM share price has dipped by 11.96%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Apollomics, Inc.’s (APLM) Stock Is Down 12.75%
As of Tuesday, June 23, Apollomics, Inc.’s APLM share price has dipped by 12.75%, which has investors questioning if this is right time to buy.Jenna Brashear
Is Maxpro Capital Acquisition Corp (APLM) Stock a Good Investment?
Learn more about Maxpro Capital Acquisition Corp's (APLM) stock grades for Growth and determine whether this Investment Holding Companies stock meets your investment needs.Jack Gilleland
Financial Summary
| Share Statistics | APLM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $45.7 | $241.2 | 16% |
|
| Shares Out (Mil) | 1.8 | 53.4 | 7% |
|
| Institutional Ownership | 0.8% | 92.9% | 2% |
|
| Float (Mil) | 0.5 | 41.2 | 1% |
|
| Beta | 1.44 | 0.96 | 81% |
|
| Avg Daily Volume (000s) | 22 | 486 | 23% |
|
| Price Change (52-week) |
6.7% | 48.4% | 58% |
|
| Growth | APLM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 37.4% | 12.8% | 93% |
|
| Net Income (5yr) | 32.0% | (10.1%) | 86% |
|
| EPS (5yr) | 18.2% | 15.8% | 65 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.8%) | (15.7%) | 42% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | APLM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $9 | $37 | 8% |
|
| Net Income (TTM) (Mil) | ($11) | ($44) | 29% |
|
| EPS (TTM) | ($7.565) | ($1.600) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($10) | ($33) | 20% |
|
| Net Cash Flow (TTM) (Mil) | ($7) | $3 | 33% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 14% |
|
| Enterprise Value (Q1) (Mil) | $39 | $177 | 14% |
|
| Valuation | APLM | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.25 | na |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | APLM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.9% | 96% |
|
| Net Margin | (123.7%) | (73.7%) | 7% |
|
| ROA | (110.4%) | (47.3%) | 5% |
|
| ROE | na | (53.3%) | na |
|
| Liabilities to Assets | 147.5% | 29.7% | 98% |
|
| F-Score | 4 | 2 | 34% |
|
Apollomics, Inc. did not pass any screens on 10/29/2026.
